Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back by unknown




of delayed-type drug hypersensitivity reactions, 
from bedside to bench and back
Rik Schrijvers1,2*, Liesbeth Gilissen3, Anca Mirela Chiriac4,5 and Pascal Demoly4,5
Abstract 
Drug hypersensitivity reactions (DHR) have been present since the advent of drugs. In particular T-cell mediated 
delayed-type hypersensitivity reactions represent a heterogeneous clinical entity with a diverse pathogenesis and 
result in a considerable burden of morbidity and mortality not only driven by the reactions themselves but also by 
the use of alternatives which are sometimes less effective or even more dangerous. Diagnostic procedures rely on 
clinical history, skin testing and potential provocation testing, whereas validated in vitro diagnostic procedures are still 
lacking for most of them. Recent work in the field of pharmacogenomics combined with basic scientific research has 
provided insights in the pathogenesis of abacavir and carbamazepine hypersensitivities linked with certain human 
leucocyte antigen risk alleles. Nevertheless, important scientific questions on how other DHR arise and how host-drug 
interactions occur, remain unanswered. Recent work indicates an intricate relation between host, drug and pathogens 
in severe cutaneous and systemic reactions and provides more insights in the role of regulatory T-cells and viral reac-
tivation in these reactions. In this review we focus on type IV delayed-type DHR, and address recent advances in the 
pathogenesis, pharmacogenomics, and diagnosis of these reactions with an emphasis on the understandings arising 
from basic research.
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Background
Drug hypersensitivity reactions (DHR) are defined as 
adverse events resembling clinical allergy to an otherwise 
safe and effective therapeutic agent. Only those in which 
an immunological mechanism can be demonstrated, 
mostly after an allergy workup, are termed drug aller-
gies [1]. They constitute approximately 15% of all adverse 
drug reactions and affect more than 7% of the general 
population [2]. They result in a considerable morbidity 
and mortality and will remain to be so in everyday patient 
care with the ever-increasing armamentarium of drugs. 
DHR have been present since the advent of drugs. Still, 
validated diagnostic procedures are lacking for many of 
them. Moreover, important scientific questions on how 
these DHR arise and how host-drug interactions occur, 
remain to be elucidated.
Clinically, DHR are classified as immediate (typically 
<1  h following the last intake of the culprit drug) or 
delayed-type DHR (DTH, typically >1 h to days after the 
start of a treatment with the culprit drug) [2]. Immedi-
ate reactions present as urticaria, angioedema, bron-
chospasm or anaphylaxis, whereas for DTH the clinical 
spectrum is much wider ranging from fixed drug erup-
tion (FDE), maculopapular eruption (MPE), general exfo-
liative dermatitis or erythroderma, drug reaction with 
eosinophilia and systemic symptoms (DRESS syndrome), 
drug-induced hypersensitivity syndrome (DIHS), acute 
generalized exanthematous pustulosis (AGEP), Stevens-
Johnson syndrome (SJS), toxic epidermal necrolysis 
Open Access
*Correspondence:  Rik.Schrijvers@uzleuven.be 
2 Department of Internal Medicine, University Hospitals Leuven, Leuven, 
Belgium
Full list of author information is available at the end of the article
Page 2 of 10Schrijvers et al. Clin Transl Allergy  (2015) 5:31 
(TEN), other bullous reactions mimicking pemphigus 
vulgaris or bullous pemphigoid up to vasculitis (Table 1). 
In particular erythroderma, DRESS, AGEP, SJS and TEN, 
often referred to as severe cutaneous adverse reactions 
(SCARs), are potentially life-threatening, with an esti-
mated mortality rate of 5–15, 10, 5, 1–5 and 20–30% 
respectively [3]. Internal organs can be affected as well, 
either alone or with cutaneous symptoms (as in DRESS 
and SJS/TEN), and may include hepatitis, nephritis, 
pneumonitis and cytopenias.
DHR are classified according to the Gell and Coombs 
classification, with type IV hypersensitivity reactions 
accounting for the T-cell mediated, and the majority of 
DTH. Pichler et al. has subdivided type IV reactions into 
4 groups according to the clinical presentation and the 
involvement of different types of drug-responsive T-cells 
(Table 1) [4].
In this review we focus on type IV DTH and address 
recent advances in the pathogenesis, pharmacogenomics, 
and diagnosis of these reactions with an emphasis on the 
understandings arising from basic research.
Pathogenesis
Scrutinizing the pathogenesis of DTH focuses on the 
interaction of drugs with the immune system. Multi-
ple mutually non-exclusive hypotheses explaining the 
pathogenesis of DHR, including DTH, exist and include 
the (pro)hapten hypothesis, the pharmacological interac-
tion (p-i) concept and the altered self-repertoire model 
(summarized in Fig. 1), as well as the danger model. For 
most models, examples have been elaborated and some 
proofs exist.
First, a drug can act as a hapten (or prohapten, if a 
reactive metabolite acts as the hapten) whereby covalent 
binding to proteins or other larger molecules results in 
the formation of an antigen. This (pro)hapten hypothesis 
is still considered the primary pathway by which chemical 
sensitizers cause allergic contact dermatitis, and it is also 
identified as a well-known pathway for β-lactam hyper-
sensitivity [1, 5]. Using mass spectrometry, conjugates of 
β-lactam antibiotics, such as benzylpenicillin derivates, 
but also piperacillin, meropenem, or aztreonam, bound 
to specific lysine residues on serum albumin resulting 
in the formation of an antigenic epitope, were identified 
and/or detected in patient plasma [6]. Next, synthetic 
β-lactam-albumin conjugates were able to stimulate pre-
viously identified drug-specific T-cell clones in an in vitro 
lymphocyte proliferation assay (LPA) [7, 8], corroborat-
ing with the (pro)hapten hypothesis in DTH [9].
Second, according to the p-i concept [the pharmaco-
logical interaction with immune receptor (p-i)], certain 
drugs interfere with the antigen presenting process, 
without the requirement of a specific peptide ligand, but 
through non-covalent interaction with human leucocyte 
antigen (HLA) alleles and/or T-cell receptors (TCR), to 
trigger an immune response [10]. This hypothesis ena-
bles to explain why some drugs, for instance contrast 
media, would generate an eruption already at the first 
Table 1 Classification of DHR according to Gell and Coombs and adapted by Pichler et al. [4]
Table adapted from [2].
Type Type of immune response Pathophysiology Clinical symptoms Typical chronology of the  
reaction
I IgE Mast cell and basophil  
degranulation
Anaphylactic shock, Angio- 
oedema, Urticaria, Bronchospasm
Within 1–6 h after the last intake of 
the drug
II IgG and complement IgG and complement- 
dependent cytotoxicity
Cytopenia 5–15 days after the start of the 
eliciting drug
III IgM or IgG and complement  
or FcR
Deposition of immune  
complexes
Serum sickness, urticaria,  
vasculitis
7–8 days for serum sickness/
urticaria
7–21 days after the start of the 
eliciting drug for vasculitis
IVa Th1 (IFNγ) Monocytic inflammation Eczema 1–21 days after the start of the 
eliciting drug
IVb Th2 (IL-4 and IL-5) Eosinophilic inflammation MPE, DRESS 1 to several days after the start of 
the eliciting drug for MPE
2–6 weeks after the start of the 
eliciting drug for DRESS
IVc Cytotoxic T-cells (perforin, gran-
zyme B, FasL)
Keratinocyte death mediated by 
CD4 or CD8
FDE, MPE, SJS/TEN, Pustular  
exanthema
1–2 days after the start of the elicit-
ing drug for fixed drug eruption
4–28 days after the start of the 
eliciting drug for SJS/TEN
IVd T-cells (IL-8/CXCL8) Neutrophilic inflammation AGEP Typically 1–2 days after the start of 
the eliciting drug (but could be 
longer)
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contact, i.e. without a known prior sensitization step. 
Here, pre-activated drug-specific T-cells present in these 
patients are hypothesized to display cross-reactivity for 
the drug-antigen presenting complex and circumvent 
the classical antigen processing steps [11]. Yang et  al. 
failed to demonstrate carbamazepine-modified peptides 
presented by HLA-B*15:02, a known risk allele for car-
bamazepine-induced SJS/TEN in certain Asian popula-
tions [12], but detected HLA-B*15:02-specific peptides 
and carbamazepine alone, suggesting a non-covalent 
interaction [13]. Next, allopurinol- or its metabolite oxy-
purinol-specific T-cell lines were demonstrated to react 
immediately (after seconds to minutes) to the addition of 
the drug, bypassing intracellular antigen processing—as 
demonstrated by the lack of inhibition by pretreat-
ment with a proteasome inhibitor—and were not lim-
ited to a particular TCR Vβ-pattern, consistent with the 
p-i concept [14]. An increased affinity of oxypurinol to 
the peptide-binding groove of HLA-B*58:01 was calcu-
lated in silico, and put forward as an explanation for the 
increased risk for allopurinol-induced DTH associated 
with this specific HLA-type [14].
Ensuing on the p-i concept, the altered self-reper-
toire model emerged based on findings explaining the 
increased risk for DTH upon abacavir-exposure in HLA-
B*57:01 positive individuals. Here, mass spectrometry on 
HLA-associated peptides in the presence or absence of 
abacavir along with crystal structure data, demonstrate 
Fig. 1 Schematic examples for the (pro)hapten hypothesis, p-i concept and altered self-repertoire model (adopted from Ostrov et al. [16]). Upper 
part TCR monitor the antigens or ligands presented by the HLA molecules. These HLA ligands are typically peptides loaded onto the HLA molecule 
inside the antigen-presenting cells and subsequently exposed on the surface. Different allelic variants of HLA molecules result in different binding 
specificities and a specific profile of presented ligands. Here, peptide A, but not peptide B, can bind to the HLA molecule. Typically, T-cells do not 
react to presented self-peptides, as these auto-reactive T-cells are negatively selected during thymic development, but will react once they encoun-
ter an unknown ligand (e.g., a virus-derived peptide). In the lower part, three scenarios in which drugs can result in a HLA-dependent reaction: in (1) 
a HLA-specific drug haptenated peptide is presented, according to the (pro)hapten hypothesis; in (2) the HLA molecule itself is modified in a region 
exposed to the TCR, resulting in a reaction according to the p-i concept; and in (3) the binding specificity of the HLA molecule is altered by the pres-
ence of the drug, resulting in presentation of novel ligands such as peptide B, as in the altered self-repertoire hypothesis.
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that abacavir lies across the bottom of the HLA-B*57:01-
binding groove, interacting with several peptide binding 
pockets (C, D, E) but predominantly protrudes into the F 
pocket, thereby altering the repertoire of usual presented 
peptides (Fig.  2) [15–17]. Moreover, abacavir interacts 
with the two residues (D114 and S116) distinguishing 
HLA-B*57:01 from HLA-B*57:03, thereby explaining the 
lack of association with the latter HLA-type [16]. The 
resulting T-cell response is not mono- or oligoclonal as 
observed in cases where a drug induces a single novel 
antigenic epitope, but polyclonal as illustrated by the 
unbiased TCR Vβ-pattern and antigen-binding com-
plementarity-determining region 3 in patient-derived 
abacavir-selective T-cells [15]. Together these data indi-
cate that the normally self-tolerant T-cell compartment is 
exposed and activated by neo-self peptides presented by 
the HLA-B*57:01-abacavir complex. In line, Lucas et  al. 
recently isolated abacavir-specific CD8+ T-cells from 
abacavir-unexposed healthy HLA-B*57:01 positive indi-
viduals from both the memory and naïve CD8+  T-cell 
compartment, indicating the existence of pre- and/or 
de novo primed CD8+ T-cells recognizing the abacavir-
altered self-peptide via cross-recognition with a hith-
erto unknown foreign antigen in the case of pre-existing 
memory CD8+ T-cells [18]. These findings correlate with 
clinical data demonstrating that HLA-B*57:01 individu-
als exposed to abacavir can develop a DTH ranging from 
as early as 48  h up to 6  weeks after the first exposure. 
However, why only 55% of HLA*B-57:01-positive indi-
viduals experience abacavir hypersensitivity, although 
drug-specific T-cells can be identified in  vitro in 100% 
of HLA-B*57:01 positive and 0% in HLA-B*57:01-nega-
tive individuals, remains to be elucidated [18]. A second 
example for this model comes from studies of the associ-
ation of HLA-B*15:02 with carbamazepine-induced SJS/
TEN. Here, in silico work suggested that carbamazepine 
likewise binds to the HLA-B*15:02 molecule, yet at sec-
ondary anchor sites (i.e., underneath the P4/P6 residues 
of the presented peptide), resulting in a smaller shift in 
presented peptides compared with that observed with 
abacavir in HLA*B-57:01 [15]. Recently, also for dapsone-
induced hypersensitivity syndrome, HLA-B*13:01 was 
identified as a risk-allele [19]. What distinguishes HLA-
B*13:01 from other HLA-B*13 alleles are three amino-
acid residues (at position 94, 95, 145) located at the 
peptide-binding groove and binding pocket F, suggesting 
similarities with the examples of abacavir and carbamaz-
epine. However, further insights in the immunopatho-
genesis of the dapsone hypersensitivity syndrome remain 
to be elaborated.
Fig. 2 Abacavir-induced altered self-peptide presentation (adopted from Ostrov et al. [16] and Yun et al. [25]). a Crystal structure of a peptide, 
HSITYLLPV or Pep-V (cyan) bound to HLA-B*57:01 (gray) together with abacavir (shown as spheres, orange for carbon, blue for nitrogen, and red for 
oxygen) [16]. b Without abacavir, the HLA-B*57:01 presents the ‘normal’ self-repertoire peptides and thus does not trigger an immune response 
(left). In the presence of abacavir, the drug can be incorporated in the F pocket of the HLA molecule thereby altering the peptide repertoire that is 
loaded onto this molecule. Abacavir binding favors binding of peptides with tryptophan (W) or phenylalanine at the C-terminus (position 9) rather 
than the small aliphatic residues (e.g., valinine, alanine, or isoleucine) which are normally bound to unmodified HLA-B*57:01 [16, 28]. This results in 
recognition of neo-antigens by neo-antigen primed CD8+ T-cells (middle). On the right, a hypothetical model of how abacavir might result in the 
selection of shorter peptide or is recognized itself by the TCR [25].
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Finally, according to the danger model the barrier for 
the development of DHR may be overcome if other risk 
factors are present. According to this model proposed by 
Matzinger [20], the immune system is more concerned 
with potential danger than foreignness [21]. Therefore 
an exogenous pathogen or chemical, or an endogenous 
intracellular molecule released from necrotic cells, might 
not evoke an immune response unless the immune sys-
tem detects ‘danger’ [22, 23]. In the absence of danger, 
tolerance will result. Therefore, it is hypothesized that 
concomitant exposure to other signals such as chemi-
cals, drugs or infectious agents, can trigger or amplify 
the innate immune response, resulting in amplification of 
insufficient stimuli over a critical threshold, thereby ena-
bling DTH to occur [24]. For instance in the case of an 
infection, inflammatory cytokines that are produced by 
the innate immune system in response to the pathogen 
might provide a danger signal that directly or indirectly 
enables the generation or activation of drug-specific 
T-cells. On the other hand, this could also explain why 
in the absence of these co-stimuli, testing for DTH later 
could remain negative. Although this hypothesis, con-
sidered additive to the other models, might be consistent 
with certain clinical observations, it currently lacks clear 
experimental evidence. Next, many questions remain 
unanswered such as why some drugs induce stress and/
or cell death, but apparently do not result in an immune 
reaction as in the example of paracetamol-induced hepa-
totoxicity [23].
Pharmacogenomics
During the last decade many associations between 
HLA molecules and the development of certain DHR 
have been reported (Table  2 and reviewed in [25]). The 
strongest associations have been described for HLA-
B*57:01 with the abacavir hypersensitivity syndrome, 
HLA-B*15:02 with carbamazepine-induced SJS/TEN, 
and HLA-B*58:01 with allopurinol-induced severe cuta-
neous adverse reactions [26]. Most associations are with 
class I but also class II molecules are described, both with 
varying degrees of association [26]. Next, also ethnicity 
plays a role, possibly reflecting in part the differences in 
HLA-backgrounds. However, HLA-associations do not 
explain all cases, indicating additional factors contribute 
to the mechanisms of drug hypersensitivity. Linkage dis-
equilibrium and the presence of certain TCR clonotypes 
have been considered as a potential explanation for these 
discrepancies.
Carbamazepine hypersensitivity is found to be asso-
ciated with HLA-B*15:02 in most Asian populations, 
but not Japanese or Korean, and with HLA-B*31:01 in 
Europeans, although this was not reported consistently 
in all studies [12, 27, 28]. In the Han Chinese popula-
tion, HLA-B*15:02 was present in 100% of the SJS/TEN 
patients [29]. However this risk-allele was also found in 
3% of carbamazepine-tolerant individuals, in 8.6% of the 
general population, and no association was observed 
in Caucasian or Japanese populations, although here a 
lower incidence of HLA-B*15:02 is observed, nor was 
there an association with carbamazepine-induced MPE, 
indicating additional associated risk factor(s) are yet 
to be identified [12]. Ko et  al. provided strong evidence 
that in addition to the associated HLA allele, particu-
lar TCRs play a role in the development of the immune 
response in the case of carbamazepine-induced SJS/TEN 
in HLA-B*15:02 positive individuals [30]. They identified 
a skewed and restricted TCR usage in affected patients 
and identified these clonotypes in blister fluid cells from 
patients. The identified TCR clonotypes (predominantly 
Vβ-11-ISGSY and Vβ-11-GLAGVDNY) were absent in 
11 carbamazepine-tolerant subjects of whom 2 carried 
the HLA-B*15:02 risk allele. Moreover, the two clono-
types could be observed in respectively 4/29 (14%) and 
2/29 (7%) of healthy carbamazepine-unexposed HLA-
B*15:02-positive subjects in whom a cytotoxic response 
could be identified in vitro in the presence of carbamaze-
pine, suggesting these patients would develop a SJS/TEN 
if exposed in vivo. The in vitro cytotoxic response could 
be blocked with an antibody against TCR-Vβ-11, suggest-
ing routes for future therapeutic strategies. Of note, these 
Table 2 Well-defined HLA associations in DHR [28]
NPV negative predictive value, PPV positive predictive value, NNT numbers needed to test (to prevent one case), ABC HS abacavir hypersensitivity syndrome.
Drug Syndrome HLA allele HLA carrier rate NPV PPV (%) NNT
Abacavir ABC HS B*57:01 [31, 34] 5–8% Caucasian 100% 55 13
Allopurinol SJS/TEN and DRESS/DIHS B*58:01 [25] 9–11% Han Chinese
1–6% Caucasian
100% in Han Chinese 3 250
Carbamazepine SJS/TEN B*15:02 [12, 27, 28] 10–15% Han Chinese 100% in Han Chinese 3 1,000
Dapsone DRESS/DIHS B*13:01 [25] 28% Papuans, Australian aborigines;  
2–20% Chinese; 1.5% Japanese; 1–12% 
Indian; 2–4% Southeast Asians
99.8% 7.8 84
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findings are consistent with the observations of a smaller 
shift in presented peptides by HLA-B*15:02 upon expo-
sure to carbamazepine compared with the shift observed 
with HLA-B*57:01 exposed to abacavir in  vitro [15]. In 
the former, a smaller shift of presented peptides might 
also explain a more biased T-cell response. However, also 
direct interaction, without the presence of loaded altered 
peptides, has been suggested for carbamazepine and 
HLA*B-15:02 [28].
Abacavir hypersensitivity is associated with HLA-
B*57:01 probably in most ethnic groups [31]. However, 
it is a rare HLA-type (<1% [32]) in Taiwanese or Korean 
populations where abacavir hypersensitivity is less fre-
quent and might be mediated via other mechanisms 
[32, 33]. DHR after abacavir exposure are potentially 
life-threatening, CD8+  T-cell mediated, HLA-B*57:01-
restricted, and previously occurring in ~5% of treated 
individuals [34]. HLA-B*57:01 screening has  a negative 
predictive value (NPV) of 100% for abacavir hypersensi-
tivity syndrome and a positive predictive value (PPV) of 
58% [34, 35], precluding further use of abacavir in case of 
positivity.
Next, HLA-B*58:01 is associated with a risk for allopu-
rinol (or its metabolite oxypurinol) induced DRESS or 
SJS/TEN, mostly in Han Chinese [14] with a PPV of 2.7–
18% [25].
Recently, HLA-B*13:01, present in 28% of Papuans and 
Australian aborigines, 2–20% of Chinese, 1.5% of Japa-
nese, 1–12% of Indian, 2–4% Southeast Asians but largely 
absent in Europeans and Africans, was identified as a risk 
factor for dapsone hypersensitivity syndrome, developing 
in 0.5–3.6% of treated individuals. HLA-B*13:01 had an 
estimated PPV of 7.8% and NPV of 99.8% [19].
The findings from pharmacogenomic studies are highly 
translational. Current HIV guidelines recommend HLA-
B*57:01 testing prior to initiating abacavir treatment 
[36]. The Food and Drug Administration recommends 
screening for HLA-B*15:02 before starting a treatment 
with carbamazepine in patients with ancestry in at-risk 
populations [37]. Also, the use of a HLA library contain-
ing different HLA molecules to screen new drugs for 
their ability to bind these molecules as a screen for their 
potential to cause severe DHR has been proposed [38]. 
The development of congeners that retain pharmacologi-
cal activity, but do not cause immune reactions could be 
imagined [2].
Relation between host, drug and pathogen
Recent work suggests an intricate relation between the 
host, drug and pathogen in severe cutaneous and sys-
temic reactions, in particular in DRESS or DIHS [26]. 
Drugs typically involved in DRESS comprise antibiotic 
sulphonamides, anticonvulsants, β-lactam antibiotics, 
allopurinol, NSAIDs, and nevirapine and for most of 
these drugs, an association with the reactivation of latent 
human herpes viruses (HHVs such as EBV, CMV, HHV-
6, and HHV-7), in some cases sequentially [39], has been 
observed [40, 41]. However, not always cell free viral 
load but also increase in virus-specific immunoglobulins 
have been used as a measure for viral reactivation [42–
44]. Whether HHV reactivation is a complication or an 
innocent bystander phenomenon rather than a cause of 
drug-induced DRESS/DIHS remains a matter of debate 
[26, 43]. HHV reactivation may be associated with more 
severe reactions [45] and viral reactivation correlated 
with the degree of inflammation [41]. Reactivation can 
be asymptomatic, but is also associated with prolonged 
symptoms in DRESS, long after stopping the causative 
drugs, or may cause organ-specific viral disease [46]. 
The demonstration of HHV reactivation may be a useful 
marker for the diagnosis of DRESS, and has been added 
to the DRESS-scoring criteria in Japan [39]. In contrast 
to DRESS/DIHS, viral reactivation seems to be uncom-
mon to occur in other severe cutaneous DHR such as 
SJS/TEN, AGEP.
What might be the relation of viral reactivation with 
DRESS/DIHS? It has been hypothesized that in the pres-
ence of viral replication, co-stimulatory molecules are 
up-regulated, lowering the threshold that is required 
for T-cell activation. Also, virus-specific T-cells from 
previous immunization may cross-react with drug-
altered HLA-presented peptides according to the heter-
ologous immunity model [28]. Picard et al. demonstrated 
expanded populations of CD8+  T-cells from DRESS 
patients recognizing EBV epitopes [47], although this 
awaits further independent confirmation [26]. Next, the 
drug may interact more favorably with viral peptides 
loaded onto HLA molecules, stimulating T-cell responses 
[25]. Also, the direct activation of virus production by 
culprit drugs has been suggested and demonstrated for 
EBV in EBV-transformed B-lymphocytes from patients 
with DRESS [47]. Finally, when the causative drug or con-
comitant drugs induce a degree of immunosuppression, 
the altered immune conditions might facilitate reactiva-
tion of latent HHVs.
Skin-resident memory T-cells and regulatory T-cells 
in DTH
Recent studies have shown that after viral infection, 
a small fraction of memory T-cells persist in periph-
eral tissues such as the skin and are considered tis-
sue-resident memory T-cells (Trm, characterized as 
CD69+ CD103+ CD8+ T-cells) [41, 48, 49]. These skin-
resident memory T-cells may also play an important role 
in DHR, in particular in FDE [41, 50]. For instance, Trm 
in resting lesions evolved to protect epidermal tissue 
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from invading pathogens might cross-recognize a drug 
antigen, resulting in localized epidermal damage upon 
exposure to the eliciting drug. This hypothesis would 
explain the intriguing observation of why FDE lesions 
often appear at exactly the same site as a previous HSV 
infection or trauma [50]. It has also been proposed that 
Trm cells develop after an abacavir hypersensitivity 
syndrome as suggested by positive patch testing in 79% 
of cases versus negative patch testing in HLA-B*57:01-
positive yet abacavir-naïve individuals, although in both 
groups circulating abacavir-reactive T-cells could be 
identified. The authors suggest a prior systemic reaction 
to be necessary to generate Trm cells that hence enable 
positive patch testing [51]. These abacavir-specific-Trm 
cells however remain to be identified. These findings also 
indicated that patch testing in HLA-B*57:01-positive 
abacavir-naïve individuals probably cannot distinguish 
between those who will and those who will not develop 
an abacavir hypersensitivity syndrome upon exposure.
FoxP3+  regulatory T-cells (Tregs) suppress effector 
T-cells and play a pivotal role in the balance between 
increased susceptibility for infections and autoimmunity 
and the role of Tregs in DTH is increasingly being recog-
nized. Tregs expand at the acute stages of DRESS/DIHS 
but decrease and become functionally deficient upon res-
olution of DRESS/DIHS, possibly explaining the delayed 
onset and viral activation at the acute stage and the risk 
of subsequent autoimmune disease upon resolution [52]. 
Alternatively in SJS/TEN, the suppressive function of 
Tregs was reduced in the acute stage, possibly reflecting 
increased epidermal toxicity at this stage [52]. Recently, 
also a case where drug-specific Tregs were increased dur-
ing the recovery stage was described [53]. Next, Tregs 
were demonstrated to play a role in FDE. Tregs migrate 
to the extending edges of the inflammatory sites of FDE, 
where they inhibit intradermal CD8+  cytotoxic T-cells 
and prevent further disease progression [54].
Diagnosis of DTH
Diagnosis of DTH after systemic administration remains 
difficult in everyday clinical practice. Currently, once a 
patient presents with a potential DTH, assessment of 
causality is based on a clinical judgment evaluating the 
relationship between drug intake and the time of onset, 
type of drug and aspect of the adverse reaction. This 
approach often leads to the eviction of numerous drugs 
and drug classes and/or the switch towards suboptimal 
alternatives. Clarification of the culprit drug(s) and/or 
chemicals, identification of potential cross-reactive mol-
ecules and safe alternatives require a complete allergy 
workup including skin testing [55–57] followed by a drug 
provocation test if indicated and if no contra-indications 
exist [2]. These in vivo tests can only be performed after 
a certain delay (at least after healing of the initial reac-
tion) and are accompanied with the risk for re-eliciting 
symptoms (locally and/or systemically), fueling research 
for validated in vitro tests. Moreover, both clinicians and 
researchers working in the field of DHR agree that there 
is a need for diagnostic tools, in particular for the diag-
nosis of severe cutaneous DHR, or those DHR affecting 
internal organs including the liver, lungs, kidneys, and 
bone marrow. The development of tools for biological 
diagnosis is indeed crucial for those cases where a drug 
provocation test is not possible.
The presence of drug-specific T-cells that are not 
detected in tolerant (exposed) controls plays a central 
role in the pathogenesis of almost all known forms of 
DTH. Therefore, the most commonly used in vitro test, 
the LPA, aims to detect these drug-specific T-cells as a 
marker of sensitization. The assay is based on the incu-
bation of freshly isolated peripheral blood mononuclear 
cells (PBMCs) from hypersensitive patients with titrated 
concentrations of the suspected drug or a vehicle control 
enabling the determination of a stimulation/prolifera-
tion-index 5–7 days later. Although safe and able to test 
many different drugs in various types of DTH, the assay 
is technically demanding, subject to toxicity issues, and 
unable to evaluate drug metabolites or most drug anti-
gens acting as haptens. Moreover, although specificity of 
the LPA is high (at least 85% [58]), the sensitivity of the 
assay is rather low (~60 to 70% [59]) and probably reflects 
the low frequency of drug-specific T-cells in hypersensi-
tive patients (estimated to be 1:250 to 1:10,000 [60]) and/
or insufficiently sensitive read-out. Currently, a DHR 
cannot be ruled out in case a negative result is obtained. 
The sensitivity also depends on the type of reaction, with 
low sensitivities being reported in CD8+ T-cell mediated 
reactions [1].
To improve the sensitivity of this in  vitro assay, sev-
eral strategies have been evaluated recently. Addition of 
anti-CTLA4 and anti-PDL1 to LPA cultures increased 
the sensitivity of the assay with more positive LPA assays 
and an increased proliferation index in already posi-
tive cases [61]. Similarly, removal of Tregs from in vitro 
stimulated cell cultures, increased sensitivity of the LPA 
from 25 to 82% as well as the overall stimulation-index 
whilst preserving specificity [62]. In 15 patients with SJS/
TEN, the LPA alone had a sensitivity of only 27%, whilst 
a combined approach evaluating granulysin expression 
in CD4+  T-cells, together with a granzyme B enzyme-
linked immunosorbent spot (ELIspot) and IFNγ produc-
tion, provided a sensitivity of 80% and specificity of 95% 
[63]. Similarly, Polak et al. compared LPA with cytokine 
assays in the acute phase in 43 patients with DHR during 
and/or after the acute phase and observed a high speci-
ficity: 95% for the LPA, 83% for IFNγ detection and 92% 
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for IL-4 detection, with a sensitivity of 82% for the com-
bined IFNγ and IL-4 detection versus only 50% for the 
LPA in the acute setting [64].
In order to evaluate the profile of drug-activated 
T-cells, alternative techniques have been developed such 
as flow cytometry–based methods using carboxyfluores-
cein diacetate succinimidyl ester staining alone [60] or in 
combination with 5-bromo-2-deoxyuridine [53] enabling 
the specific characterization of the fraction of prolifer-
ating cells in the LPA. The evaluation of more surface 
markers of T-cell activation (e.g. CD69, CD107a, CD40L 
and HLA-DR), and the evaluation of cytokine secre-
tion using the antibody-based ELIspot assay to quantify 
the number of cytokine-secreting cells in antigen-stim-
ulated PBMCs have been studied as well [1]. The latter 
has the advantage that low numbers, as low as 1:30,000, 
of drug-specific T-cells can be detected [65]. A panel of 
ELIspot assays to detect IFNγ, IL-4, IL-5, IL-13, IL-17, 
IL-22, FasL, TNF-α, granzyme B, and perforin producing 
T-cells is currently being investigated [1]. Most of these 
assays resulted in improved sensitivities whilst preserv-
ing specificity, indicating considerable progress in the 
in vitro diagnosis of DTH [64].
Next, Adachi et  al. suggested combined testing for 
DTH using the basophil activation test and LPA and 
observed that samples that yielded positive results for 
LPA and basophil activation test did not overlap, suggest-
ing that the two analyses might compensate each other 
for false-negativity. Combined sensitivity was higher 
compared with the sensitivity for the single assays (NPV 
of 14.7% for the basophil activation test, 28.2% for the 
LPA, and 96.4% for the combination) [66].
Recently, an alternative assay using the determination 
of IL-6 production early (20 min) after in vitro exposure 
of PBMCs to suspected drugs in a heterogeneous patient 
population (both immediate and DTH were evaluated) 
was reported to have a sensitivity and specificity of 
respectively 85 and 82%, yet it awaits further validation 
[67].
Conclusions
In conclusion, considerable progress has been made in 
our understandings of the disease mechanisms in various 
DTH, with the best examples coming from HLA-asso-
ciated DHR with abacavir, carbamazepine and allopuri-
nol. Whether or not these findings can be extrapolated 
to other DTH remains to be elucidated. The complex 
interplay between host, drug and other potential factors 
such as infectious diseases and/or environmental factors 
remains to be explored. Nevertheless, pharmacogenomics 
studies have paved the way for pre-treatment screening 
for potentially severe DHR and further work in this field 
is highly anticipated. Also, improvements in the in  vitro 
diagnostics will most likely enhance our understandings 
of DTH, and aid in the daily clinical practice of diagnosis 
and proper management of drug hypersensitivities.
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